Pharmacoeconomic review report : (Novartis Pharmaceuticals Canada Inc.) : indication : once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airway diseaseIndacaterol/mometasone furoate (Atectura Breezhaler)
Based on CADTH reanalyses, for patients who require low-dose or medium-dose combinations of inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) (ICS/LABA), less expensive options are available that could achieve very similar health outcomes to indacaterol/mometasone furoate (QMF). Therefore, for QMF to be considered cost-effective in these patients, QMF should be priced no more than the least expensive available alternative. For patients who require a high-dose ICS/LABA combination, QMF 150 mcg/320 mcg is less expensive than all alternative comparators and is likely associated with similar health outcomes, making it cost-effective in these patients. CADTH was unable to address the cost-effectiveness of QMF relative to other currently available ICS/LABA treatments due to lack of evidence. In CADTH's reanalyses, it was assumed that current ICS/LABA options, at similar doses, would achieve similar health outcomes. There is no clinical evidence to support a price premium for QMF above similarly dosed ICS/LABA combinations. The cost-effectiveness of QMF among adolescents is uncertain as the sponsor's analysis reflects a predominately adult population and no subgroup analysis was performed..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
January 2021 |
|---|---|
| Erschienen: |
Ottawa: Canadian Agency for Drugs and Technologies in Health ; January 2021 |
| Ausgabe: |
Version: Final (with redactions). |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Anti-Asthmatic Agents |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed November 2, 2021) |
|---|
| Umfang: |
1 online resource (1 PDF file (32 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1780637888 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1780637888 | ||
| 003 | DE-627 | ||
| 005 | 20230428082346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211208s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1780637888 | ||
| 035 | |a (DE-599)KEP071055991 | ||
| 035 | |a (OCoLC)1288150529 | ||
| 035 | |a (NCBI)9917779383406676 | ||
| 035 | |a (EBP)071055991 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Pharmacoeconomic review report |b (Novartis Pharmaceuticals Canada Inc.) : indication : once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airway diseaseIndacaterol/mometasone furoate (Atectura Breezhaler) |
| 250 | |a Version: Final (with redactions). | ||
| 264 | 1 | |a Ottawa |b Canadian Agency for Drugs and Technologies in Health |c January 2021 | |
| 300 | |a 1 online resource (1 PDF file (32 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed November 2, 2021) | ||
| 520 | |a Based on CADTH reanalyses, for patients who require low-dose or medium-dose combinations of inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) (ICS/LABA), less expensive options are available that could achieve very similar health outcomes to indacaterol/mometasone furoate (QMF). Therefore, for QMF to be considered cost-effective in these patients, QMF should be priced no more than the least expensive available alternative. For patients who require a high-dose ICS/LABA combination, QMF 150 mcg/320 mcg is less expensive than all alternative comparators and is likely associated with similar health outcomes, making it cost-effective in these patients. CADTH was unable to address the cost-effectiveness of QMF relative to other currently available ICS/LABA treatments due to lack of evidence. In CADTH's reanalyses, it was assumed that current ICS/LABA options, at similar doses, would achieve similar health outcomes. There is no clinical evidence to support a price premium for QMF above similarly dosed ICS/LABA combinations. The cost-effectiveness of QMF among adolescents is uncertain as the sponsor's analysis reflects a predominately adult population and no subgroup analysis was performed. | ||
| 650 | 2 | |a Asthma |x drug therapy | |
| 650 | 2 | |a Mometasone Furoate |x therapeutic use | |
| 650 | 2 | |a Glycopyrrolate |x analogs & derivatives | |
| 650 | 2 | |a Anti-Asthmatic Agents |x economics | |
| 650 | 2 | |a Cost-Benefit Analysis | |
| 651 | 2 | |a Canada | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK568896/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 4017176933 |h h64 NCBI |y zi06404 |z 08-12-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 4017174485 |h OLR-NCB-BOOKSHELF |y xsn |z 08-12-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 401717227X |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-12-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 4016845734 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 08-12-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 4016846978 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 08-12-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 4016846994 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 08-12-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK568896/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK568896/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK568896/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK568896/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK568896/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||